MyomoNYSE American: MYO

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, chairman and chief executive officer and David Henry, chief financial officer, will present and host one-on-one meetings with investors at the Sidoti Virtual Investor conference being held on June 12-13, 2024. Management's presentat.

Myomo, Inc. will release its financial results for the first quarter of 2024 on May 8, 2024, and will hold a conference call at 4:30 p.m. ET that same day with remarks by chairman and chief executive Paul R. Gudonis.

Medicare decision created a multi-decade revenue growth opportunity. Soft Q1 guidance due to non-recurring timing issues. 2024 guidance gives only partial-year credit to reimbursement change.

Myomo, Inc. (MYO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.29 per share a year ago.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Myomo, Inc. (MYO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Market undervalues MYO stock due to poor understanding of CMS process. MYO is able to generate revenues in excess of $100mm/yr. MYO valuation gap will close before February 2024, when the final CMS price is published.

Myomo, Inc. (MYO) Q3 2023 Earnings Call Transcript

Myomo (NYSEMKT: MYO ) stock is dropping on Monday after the wearable medical robotics company priced a public share offering. A press release from Myomo highlights details of its planned public offering.

Myomo, Inc. (MYO) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.42 per share a year ago.